By: Chris Ryan From: onclive.com The FDA has approved vepdegestrant (Veppanu) for the treatment of adult patients with estrogen receptor (ER)–positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least 1 line of endocrine therapy.1,2 The approval was backed by data from the phase 3 VERITAC-2 trial (NCT05654623), which demonstrated …
Datopotamab Deruxtecan Improves Survival Outcomes in Advanced Triple-Negative Breast Cancer
By: Quincy Attobrah From: oncnursingnews.com Datopotamab deruxtecan (Datroway) demonstrated improved progression-free survival (PFS) and overall survival (OS) compared with standard chemotherapy in patients with previously untreated, advanced triple-negative breast cancer (TNBC) who were not eligible for immunotherapy, according to results from the phase 3 TROPION-Breast02 trial. The findings, published in Annals of Oncology, address a significant unmet need in TNBC, …
Combination treatment benefits patients with advanced breast cancer that has spread to brain
From: mdanderson.org Patients with leptomeningeal metastasis (LM) have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM. The Phase II study, published today in Nature Cancer, included 17 female patients with newly diagnosed LM and HER2+ breast cancer. Median overall survival (OS) in those treated with the combination therapy increased from a historical average of 4.4 months to 10 months. …
Unusual Tumor Cells May Be Overlooked Factors in Advanced Breast Cancer
From: cornell.edu An enigmatic type of circulating tumor cell called a dual-positive (DP) cell is associated with shorter survival time in patients with advanced breast cancer, according to a study led by investigators at Weill Cornell Medicine and NewYork-Presbyterian. The findings highlight the potential importance of these under-studied cells in breast cancer progression. Circulating tumors cells are breakaway tumor cells …
Overall Survival Increasing in Advanced Breast Cancer
Source: HealthDay News From: oncologynurseadvisor.com Increase seen in overall survival, especially among those with HER2+-positive cancers, with median increase of more than 10 months. For women with advanced breast cancer (ABC), overall survival is increasing, especially among those with human epidermal growth factor receptor 2 (HER2)-positive cancers, according to a study presented at the Advanced Breast Cancer Eighth International Consensus …
Supervised training boosts muscle mass and balance in advanced breast cancer patients
Source: Associação Advanced Breast Cancer Global Alliance From: news-medical.net Aerobic and resistance exercise can significantly improve physical performance in patients living with metastatic breast cancer according to new results presented at the Advanced Breast Cancer Eighth International Consensus Conference (ABC8) today (Friday). Anne May, Professor of Clinical Epidemiology of Cancer Survivorship at the University Medical Center (UMC) Utrecht and the …
Real-World Study Shows Differences in Efficacy Among CDK4/6 Inhibitors for Advanced Breast Cancer
By: Tony Berberabe, MPH From: targetedonc.com In patients with endocrine-sensitive HR-positive/HER2-negative advanced breast cancer, the cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) abemaciclib (Verzenio), palbociclib (Ibrance), and ribociclib (Kisqali) demonstrated varying real-world progression-free survival (rwPFS) outcomes, according to findings from the multicenter PALMARES-2 trial (NCT06805812) published in Annals of Oncology.1 After a median follow-up of 34.1 months, abemaciclib and ribociclib were associated …
Novel ADC IBI354 Drives Responses in Pretreated HER2+ Advanced Breast Cancer
By: Chris Ryan From:.onclive.com Key Takeaways IBI354 showed a 59.1% overall response rate and 90.9% disease control rate in HER2-positive breast cancer patients. In the 9 mg/kg subgroup, the overall response rate was 72.4%, with a disease control rate of 89.7%. Treatment-emergent adverse effects occurred in 97.6% of patients, with 39.1% experiencing grade 3 or higher events. IBI354’s mechanism includes …
Switch to Experimental Drug after Liquid Biopsy Detection of Breast Cancer Recurrence Improves Outcomes
From: cornell.edu A large prospective, randomized clinical trial in patients with advanced breast cancer has found that the use of liquid biopsy blood tests for early detection of a treatment-resistance mutation, followed by a switch to a new type of treatment, substantially extends the period of tumor control compared to standard care. The SERENA-6 study, published June 1 in the …
ADC Combination Outperforms Standard Treatment of Advanced Triple-Negative Breast Cancer
From: dana-farber.org In patients with an aggressive form of breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus pembrolizumab resulted in durable responses with improved progression free survival compared to the current standard treatment. The ASCENT-04 study presented today by Dana-Farber Cancer Institute investigators evaluated patients receiving their first treatment for advanced or metastatic triple negative breast cancer that …